Navigation Links
AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
Date:5/15/2008

QUEBEC CITY, May 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its Senior Vice President and Chief Financial Officer, Dennis Turpin, CA, will present a company overview at the upcoming Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday, May 20, 2008 at 9:40 am (local time), in the Atlantique Salon - Meridional (2nd floor) of the Meridien Beach Plaza Hotel at the Sea Club, in Monaco.

A live webcast of this presentation will be available on AEterna Zentaris' website at http://www.aezsinc.com in the Investors section. A replay will also be available for a period of 30 days on the Company's website.

Also on Tuesday, May 20, 2008, Professor, Jurgen Engel, Ph.D., Executive Vice President and Chief Scientific Officer at AEterna Zentaris will make a poster presentation at the American Urological Association's Annual Meeting, from 10:30 am to 12:30 pm (Eastern Time) in Room 315 AB of the Orange County Convention Center in Orlando, Florida. Titled, "Luteinizing Hormone-Releasing Hormone (LHRH) Receptors in BPH as Potential Molecular Targets for Therapy with Cetrorelix", the presentation will focus on the Company's lead compound, cetrorelix, which could provide rapid and long lasting improvement of symptoms in men with benign prostatic hyperplasia.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at http://www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
2. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
3. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
4. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
5. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris Announces Changes to its Management Team
8. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
9. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... of the North American Spine Society (NASS)1 demonstrate high fusion rates at ... cases, when PEEK-OPTIMA™ HA Enhanced is used for interbody-fusion devices. The implantable ...
(Date:1/17/2017)... MILPITAS, Calif. , Jan. 17, 2017 /PRNewswire/ ... today announced that it has initiated a global ... PTG-100, an oral peptide that targets alpha4beta7 integrin. ... design study is to evaluate the safety/tolerability and ... colitis patients with moderate to severe active disease. ...
(Date:1/16/2017)... -- Eurofins Genomics today announced the expansion of its Express ... their primers in a shorter turnaround time, without the ... other providers. Express oligos are available for anyone in ... additional fee. Researchers use the oligos for ... genotyping, site-directed mutagenesis, and cloning. Often, they are custom ...
(Date:1/13/2017)... , ... January 13, 2017 , ... ... products containing an organic compound called fulvic acid that farms, greenhouses and hydroponics ... that grow cannabis are among the fastest growing segments of customers using this ...
Breaking Biology Technology:
(Date:1/6/2017)... 2017  SomaLogic announced today that it has ... by iCarbonX, the China -based ... Digital Health Ecosystem that can define each person,s ... biological, behavioral and psychological data, the Internet and ... SomaLogic will provide proteomics data and applications expertise ...
(Date:1/4/2017)... 2017  CES 2017 – Valencell , the ... announced the launch of two new versions of ... biometric sensor modules that incorporate the best of ... expertise. The two new designs include Benchmark BE2.0, ... and Benchmark BW2.0, a 2-LED version of its ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... e-Government, Public Safety, HealthCare, and Finance sectors announced today that Leaders ... to implement and deploy a community-based supportive services program to reduce ... , further expanding its presence in the state. ... This new program, which is expected ...
Breaking Biology News(10 mins):